CD47 and acute myeloid leukemia: Furthermore, the anti-CD47 antibody CC-90002 was investigated in a phase 1 trial for AML and high-risk MDS, which demonstrated macrophage-mediated phagocytosis in preclinical models but limited clinical efficacy, leading to trial discontinuation [316]​.